Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
- Clinical outcomes and quality of life measures for acoramidis in variant ATTR-CM - Post-hoc analysis showing lower incidence of atrial fibrillation events - Data on serum TTR levels in both wild-type and variant ATTR-CM patients - Real-world disease progression studies - Analysis of ATTR-CM diagnosis timelines - Mortality cause analysis from the ATTRibute-CM study
The presentations feature research from leading medical institutions including University College London, Stanford University, and the University of Montreal.BridgeBio Pharma (NASDAQ: BBIO), a biopharmaceutical company specializing in genetic diseases, has announced its participation in the upcoming Bank of America Merrill Lynch Global Healthcare Conference 2025. The company's management team will engage in a fireside chat on Wednesday, May 14 at 2:20 PM PT in Las Vegas, NV.
Investors and interested parties can access the live webcast through BridgeBio's investor relations website. A replay will remain available for 30 days following the presentation.
BridgeBio Pharma reported strong Q1 2025 results, with $36.7 million in first-quarter U.S. Attruby net product revenue. The company has seen 2,072 unique patient prescriptions from 756 healthcare providers since FDA approval in November 2024.
Key highlights:
- Cash position of $540.6 million, with additional $105 million in milestone payments expected in Q2
- Total revenues of $116.6 million for Q1 2025
- Successful global expansion with BEYONTTRA approvals in EU, UK, and Japan
- Positive results in hypochondroplasia and hypoparathyroidism trials
The company's pipeline shows progress across multiple programs, including acoramidis for ATTR-CM, BBP-418 for LGMD2I/R9, and encaleret for ADH1. Notable achievements include a 42% reduction in all-cause mortality for Attruby and 78% success rate in encaleret's proof-of-principle study for hypoparathyroidism.
BridgeBio Pharma (BBIO) has received UK approval for BEYONTTRA® (acoramidis), the first near-complete TTR stabilizer (≥90%) for treating ATTR-CM (transthyretin amyloidosis with cardiomyopathy). The approval is based on the Phase 3 ATTRibute-CM study results, which demonstrated:
- 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization events at Month 30
- 50% reduction in cumulative frequency of cardiovascular hospitalization events
- Rapid benefit showing separation from placebo in as few as 3 months
BEYONTTRA is now approved in the US, EU, UK, and Japan. Under a collaboration agreement with Bayer, who will handle UK commercialization, BridgeBio will receive tiered royalties starting in the low-thirties percent on sales.
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, has scheduled its first quarter 2025 financial results conference call for Tuesday, April 29, 2025, at 4:30 pm ET. The company will release its Q1 financial results and program updates after market close on the same day.
Investors and interested parties can access the live webcast through the 'Events' page in the Investors section of BridgeBio's website. A replay will remain available for 30 days following the event. Registration for the webcast is available through a dedicated online link.
BridgeBio Pharma (BBIO) has announced new equity grants approved by its compensation committee on April 9, 2025. The grants consist of restricted stock units totaling 77,652 shares, awarded to 20 new employees.
The vesting schedule specifies that one-fourth of each employee's shares will vest on May 16, 2026, followed by quarterly vesting of one-twelfth of the remaining shares, contingent on continued employment. These inducement grants were made under the company's Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
BBOT has announced the dosing of its first patient with BBO-11818 in the Phase 1 KONQUER-101 trial for advanced solid tumors. BBO-11818 is an orally bioavailable small molecule that acts as a panKRAS dual inhibitor, binding to both 'ON' and 'OFF' states of KRAS with picomolar affinity.
The drug demonstrates sub-nanomolar to single-digit nanomolar potency in cellular assays for pERK inhibition in KRAS G12D and G12V-mutant cell lines. It shows effectiveness in reducing cell viability across KRASG12D, KRASG12V, and KRASG12C-mutant cell lines, with over 500-fold selectivity for KRAS over H- and NRAS.
This marks BBOT's third molecule entering clinical trials, positioning the company to potentially deliver combination therapy through MAPK and PI3Kα/AKT co-inhibition for patients with RAS-driven cancers.
BridgeBio Pharma (BBIO) announced significant clinical outcomes for acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM). The drug showed a 59% risk reduction in variant ATTR-CM patients and 31.2% reduction in wild-type ATTR-CM patients for the composite of all-cause mortality (ACM) and cardiovascular-related hospitalization (CVH).
Key highlights from the ATTRibute-CM Phase 3 trial include:
- Hazard ratio of 0.41 for ATTRv-CM patients
- 42% reduction in composite ACM and recurrent CVH events at Month 30
- 50% reduction in cumulative CVH events at Month 30
- Benefits observed in as few as 3 months
Acoramidis, approved as Attruby™ in the US and BEYONTTRA™ in Europe and Japan, demonstrates near-complete (≥90%) TTR stabilization. The drug showed improved outcomes in both variant and wild-type ATTR-CM patients, with statistically significant results in both subgroups.
BridgeBio Pharma (BBIO) announced the Japanese approval of Beyonttra™ (acoramidis) for treating ATTR-CM (transthyretin-mediated amyloid cardiomyopathy) in adults. The approval stems from successful Phase 3 trials, including a Japanese study reporting 0% mortality over 30 months and a global ATTRibute-CM trial showing significant benefits.
Key clinical achievements include:
- 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization events at Month 30
- 50% reduction in cumulative cardiovascular-related hospitalization events at Month 30
- Benefits observed as early as 3 months into treatment
Through its partnership with Alexion, AstraZeneca Rare Disease, BridgeBio will receive a $30 million milestone payment and low double-digit royalties on Japanese sales. Commercial launch is planned for first half 2025.
BridgeBio Pharma (Nasdaq: BBIO) has announced the presentation of cardiovascular outcomes data from their ATTRibute-CM Phase 3 study of acoramidis in ATTR-CM at the upcoming American College of Cardiology (ACC) Annual Scientific Sessions in Chicago, March 29-31, 2025.
The company will present seven studies, including five flatboard poster presentations and two moderated posters, focusing on various aspects of acoramidis treatment in ATTR-CM patients. Key presentations include:
- Acoramidis's impact on serum TTR levels in wild-type and variant ATTR-CM patients
- Improvements in NYHA Class at Month 30 versus placebo
- Effects of combining acoramidis with tafamidis
- Primary endpoint efficacy results and NT-proBNP sensitivity analyses
- Relationship between early serum transthyretin increase and reduced cardiovascular hospitalizations
- Geographic healthcare disparities in ATTR-CM diagnosis